Angiology: Open Access
Open Access

Mohammed Asserraji

Biography

In The Lancet Rheumatology, Giulio Cavalli and colleagues
¹
 report potential beneficial effects of the IL-1 receptor antagonist anakinra in patients with COVID-19, acute respiratory distress syndrome (ARDS), and hyperinflammation. In the study protocol, anakinra was given in combination with a 4-aminoquinoline and, although promising, we suggest that this combination cannot be fully synergistic in the presence of cytokine release syndrome.

Research Interest

Coronary artery calcifications, Dialysis patients, Calcium coronary Agatston score

Relevant Topics